Drug Profile
MGV 354
Alternative Names: MGV354Latest Information Update: 29 Aug 2019
Price :
$50
*
At a glance
- Originator Alcon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 29 Aug 2019 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic)
- 29 Aug 2019 Discontinued - Phase-I/II for Ocular hypertension in USA (Ophthalmic)
- 09 Apr 2019 Novartis completed the spin-off of Alcon